NCT02555618View on ClinicalTrials.gov

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Influenza Infection
Interventions
BIOLOGICAL

TAK-850

TAK-850 subcutaneous injection

BIOLOGICAL

Influenza HA vaccine

Influenza HA vaccine subcutaneous injection

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02555618 - Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants | Biotech Hunter | Biotech Hunter